Cipla Limited announced its audited consolidated financial results for the quarter and financial year ended March 31st, 2025.

Cipla has posted Total Income from Operations of Rs. 6,730 crore in Q4 FY25 as compared to Rs. 6,163 crore in Q4 FY25, reflecting a growth of 9.2%. EBITDA in Q4 FY25 grew by 16.8% at Rs. 1,538 crore as compared to Rs. 1,316 crore in Q4 FY24. The company reported 30.1% jump in Q4 FY25 PAT at Rs. 1,222 crore as compared to Rs. 939 crore in Q4 FY24.

For FY2025, Cipla posted Total Income from Operations of Rs. 27,548 crore as compared to Rs. 25,455 crore, reflecting a growth of 8.2%. EBITDA grew by 14.4% at Rs. 7,128 crore as compared to Rs. 6,233 crore in FY 2024. PAT in FY2025 grew 28.4% at Rs. 5,273 crore as compared to Rs. 4,106 crore.

“I am pleased to share that we continue to make considerable progress across our focused markets. In FY25, we recorded a revenue growth of 8% over last year with the EBITDA margin of 25.9%, driven by mix and other operational efficiencies. Our One-India business grew at a healthy 7% YoY. Key therapies in Branded Prescription business continued to outpace the market growth, Trade Generics business growth trajectory is back on track and Anchor brands of Consumer Health Business maintained leadership position. With a positive traction in our differentiated assets, the US business posted an all-time high annual revenue of $ 934 million. In One Africa, we recorded a solid growth of 12% YoY in USD terms, powered by firm performance across key markets. Emerging Markets and Europe delivered a substantial revenue growth of 15% YoY on the back of deep market focus strategy. Going ahead, the focus will be on growing our key markets, further building our flagship brands, investing in future pipeline as well as focusing on resolutions on the regulatory front,” said Umang Vohra, MD and Global CEO, Cipla Ltd